U.S. Markets close in 1 hr
  • S&P 500

    4,458.87
    +63.23 (+1.44%)
     
  • Dow 30

    34,830.94
    +572.62 (+1.67%)
     
  • Nasdaq

    15,072.84
    +175.99 (+1.18%)
     
  • Russell 2000

    2,262.63
    +44.07 (+1.99%)
     
  • Crude Oil

    73.27
    +1.04 (+1.44%)
     
  • Gold

    1,750.70
    -28.10 (-1.58%)
     
  • Silver

    22.65
    -0.26 (-1.14%)
     
  • EUR/USD

    1.1751
    +0.0055 (+0.47%)
     
  • 10-Yr Bond

    1.4080
    +0.0720 (+5.39%)
     
  • GBP/USD

    1.3734
    +0.0114 (+0.84%)
     
  • USD/JPY

    110.2400
    +0.4620 (+0.42%)
     
  • BTC-USD

    44,765.32
    +1,546.87 (+3.58%)
     
  • CMC Crypto 200

    1,123.63
    +14.71 (+1.33%)
     
  • FTSE 100

    7,078.35
    -5.02 (-0.07%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

AcelRx, Aguettant Ink Licensing Agreements For Dzuveo And Two Prefilled Syringe Products

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has agreed to provide a license to Laboratoire Aguettant to commercialize Dzuveo in Europe and give AcelRx two prefilled syringe product candidates for the U.S.

  • Under the Dzuveo licensing agreement, Aguettant will have the right to commercialize Dzuveo in Europe.

  • AcelRx will up to $55 million in a combination of up-front and sales-based milestone payments, along with revenue share payments ranging from 35% to 45% of net sales.

  • Under the terms of a separate U.S. licensing agreement, AcelRx obtained the rights to file marketing applications (subject to approval) and commercialize two of Aguettant's EU-approved, prefilled syringe ephedrine and phenylephrine products.

  • Aguettant will receive up to $24 million in sales-based milestone payments at various annual sales levels up to $60 million, along with revenue share payments of 40 to 45%.

  • Dzuveo is indicated for the management of acute pain in hospital settings.

  • Price Action: ACRX shares are up 4.92% at $1.28 during the premarket session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.